(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three most active and biggest winners today are Glory Star New Media Group Holdings Limited, Redfin, and Amicus Therapeutics.

Rank Financial Asset Price Change Updated (EST)
1 Glory Star New Media Group Holdings Limited (GSMGW) 0.01 86.05% 2022-05-12 11:10:07
2 Redfin (RDFN) 10.52 19.37% 2022-05-12 14:34:55
3 Amicus Therapeutics (FOLD) 7.28 15.66% 2022-05-12 14:58:13
4 DISH Network (DISH) 19.91 14% 2022-05-12 14:57:07
5 Fiverr (FVRR) 34.55 13.69% 2022-05-12 14:52:57
6 Bionano Genomics (BNGO) 1.39 13.47% 2022-05-12 14:48:13
7 Etsy (ETSY) 87.91 12.98% 2022-05-12 14:48:58
8 GENFIT S.A. (GNFT) 3.55 12.7% 2022-05-12 07:47:14
9 Novavax (NVAX) 47.85 11.5% 2022-05-12 14:58:34
10 Groupon (GRPN) 14.19 11.43% 2022-05-12 14:58:42

The three most active and biggest losers today are FAT Brands, Helius Medical Technologies, and Greenrose Acquisition Corp..

Rank Financial Asset Price Change Updated (EST)
1 FAT Brands (FATBW) 3.41 -31.11% 2022-05-11 19:44:11
2 Helius Medical Technologies (HSDT) 1.48 -23.71% 2022-05-12 15:11:06
3 Greenrose Acquisition Corp. (GNRS) 1.05 -16% 2022-05-12 09:06:08
4 Esports Entertainment Group (GMBLW) 0.16 -15.48% 2022-05-12 07:44:12
5 TherapeuticsMD (TXMD) 2.99 -13.63% 2022-05-12 14:51:00
6 Fortress Biotech (FBIO) 0.80 -13.25% 2022-05-11 19:46:13
7 Second Sight Medical Products (EYESW) 0.44 -12.12% 2022-05-11 19:11:05
8 Foresight Autonomous Holdings Ltd. (FRSX) 0.59 -11.14% 2022-05-12 01:15:13
9 Esports Entertainment Group (GMBL) 0.38 -10.93% 2022-05-12 07:43:14
10 Forte Biosciences (FBRX) 1.10 -10.89% 2022-05-11 19:48:13

Most Active Winners today

1. Glory Star New Media Group Holdings Limited (GSMGW) – 86.05%

Glory Star New Media Group Limited offers content and advertising production services in China. It also operates in digital media and entertainment, as well as mobile and online advertising. It also offers CHEERS App, an ecommerce platform that provides live streaming and shopping online, along with short video, dramas, variety shows and other online content. Glory Star New Media Group Holdings Limited, headquartered in Beijing in China was established in 2016.

NASDAQ ended the session with Glory Star New Media Group Holdings Limited jumping 86.05% to $0.01 on Thursday while NASDAQ rose 0.06% to $11,370.96.

Glory Star New Media Group Holdings Limited’s last close was $0.02, 10.81% under its 52-week high of $0.02.

Glory Star New Media Group Holdings Limited’s Revenue

Year-on-year quarterly revenue growth declined by 14%, now sitting on 153.01M for the twelve trailing months.

Glory Star New Media Group Holdings Limited’s Stock Yearly Top and Bottom Value

Glory Star New Media Group Holdings Limited’s stock is valued at $0.01 at 17:32 EST, way below its 52-week high of $0.02 and way higher than its 52-week low of $0.01.

More news about Glory Star New Media Group Holdings Limited.

2. Redfin (RDFN) – 19.37%

Redfin Corporation is a Canadian real estate broker. Redfin Corporation operates an online marketplace for real estate and offers real estate services. This includes assisting people in buying or selling a home. The company also offers title and settlement services, originates and sells loans and purchases and sells houses. In May 2006, the company changed its name from Appliance Computing Inc. to Redfin Corporation. Redfin Corporation was established in 2002. It is located in Seattle, Washington.

NASDAQ ended the session with Redfin jumping 19.37% to $10.52 on Thursday, after five sequential sessions in a row of losses. NASDAQ rose 0.06% to $11,370.96, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Volume

Today’s last reported volume for Redfin is 7776520 which is 187.59% above its average volume of 2703970.

Redfin’s last close was $8.81, 87.76% under its 52-week high of $71.99.

Redfin’s Sales

Redfin’s sales growth is 144.5% for the ongoing quarter and 93.2% for the next. The company’s growth estimates for the current quarter and the next is a negative 390.9% and a negative 91.9%, respectively.

Redfin’s Revenue

Year-on-year quarterly revenue growth grew by 128%, now sitting on 1.52B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Redfin’s stock is considered to be overbought (>=80).

Redfin’s Stock Yearly Top and Bottom Value

Redfin’s stock is valued at $10.52 at 17:32 EST, under its 52-week low of $11.09.

Redfin’s Moving Average

Redfin’s worth is way under its 50-day moving average of $17.94 and way under its 200-day moving average of $38.25.

More news about Redfin.

3. Amicus Therapeutics (FOLD) – 15.66%

Amicus Therapeutics, Inc. is a biotechnology company that focuses on the development, commercialization, and discovery of treatments for rare and/orphan diseases. Galafold is an oral administered small molecule pharmacological chaperone that can be used to treat Fabry’s disease. The company is currently conducting Phase 3 (ATB200–03) clinical studies of AT-GAA in Pompe disease. It has license and collaboration agreements with Nationwide Children’s Hospital, and University of Pennsylvania. Amicus Therapeutics Inc. was established in 2002. It is located in Cranbury in New Jersey.

NASDAQ ended the session with Amicus Therapeutics jumping 15.66% to $7.28 on Thursday, after two successive sessions in a row of losses. NASDAQ jumped 0.06% to $11,370.96, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Volume

Today’s last reported volume for Amicus Therapeutics is 8784030 which is 141.99% above its average volume of 3629880.

Amicus Therapeutics’s last close was $6.29, 50.2% below its 52-week high of $12.63.

Amicus Therapeutics’s Sales

Amicus Therapeutics’s sales growth is 20.1% for the ongoing quarter and 34.5% for the next. The company’s growth estimates for the present quarter and the next is 44.4% and 56%, respectively.

Amicus Therapeutics’s Revenue

Year-on-year quarterly revenue growth grew by 18%, now sitting on 293.93M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Amicus Therapeutics’s stock is considered to be overbought (>=80).

Amicus Therapeutics’s Stock Yearly Top and Bottom Value

Amicus Therapeutics’s stock is valued at $7.28 at 17:32 EST, way under its 52-week high of $12.63 and way above its 52-week low of $6.24.

Amicus Therapeutics’s Moving Average

Amicus Therapeutics’s value is way below its 50-day moving average of $8.51 and way under its 200-day moving average of $10.05.

More news about Amicus Therapeutics.

4. DISH Network (DISH) – 14%

DISH Network Corporation and its affiliates provide pay-TV services throughout the United States. It operates two business segments: Pay-TV, and Wireless. The company offers DISH TV video services. It also has programming packages which include national, regional, and local cable networks. It also offers access to TV and Internet-connected TVs, tablets and smartphones. The dishanywhere.com mobile application for tablets and smartphones allows you to remotely manage certain features, view approved content and search program listings. It also offers Sling TV services such as Sling Latino and Sling Orange and Sling Blue. These services require an Internet connection, can be accessed on any streaming-capable device, like TVs and tablets. This is primarily for consumers who don’t subscribe to cable or satellite pay-TV. It had 11.986million Pay-TV subscribers as of December 31, 2019. It offers programming and receivers through small satellite retailers and direct sales channels. DISH Network Corporation was established in 1980. It is located in Englewood in Colorado.

NASDAQ ended the session with DISH Network rising 14% to $19.91 on Thursday while NASDAQ jumped 0.06% to $11,370.96.

Volume

Today’s last reported volume for DISH Network is 12038000 which is 266.5% above its average volume of 3284500.

DISH Network’s last close was $17.46, 62.89% under its 52-week high of $47.05.

DISH Network’s Sales

DISH Network’s sales growth is 0.2% for the ongoing quarter and a decline by 1.9% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 24.2% and a negative 31.1%, respectively.

DISH Network’s Revenue

Year-on-year quarterly revenue growth declined by 1.8%, now sitting on 17.99B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

DISH Network’s stock is considered to be overbought (>=80).

DISH Network’s Stock Yearly Top and Bottom Value

DISH Network’s stock is valued at $19.91 at 17:32 EST, below its 52-week low of $21.77.

DISH Network’s Moving Average

DISH Network’s worth is way below its 50-day moving average of $30.86 and way under its 200-day moving average of $36.11.

More news about DISH Network.

5. Fiverr (FVRR) – 13.69%

NYSE ended the session with Fiverr jumping 13.69% to $34.55 on Thursday while NYSE rose 0.19% to $14,931.10.

Volume

Today’s last reported volume for Fiverr is 3845860 which is 249.3% above its average volume of 1101000.

Fiverr’s last close was $63.28, 81.17% below its 52-week high of $336.00.

Fiverr’s Sales

Fiverr’s sales growth is 35.8% for the ongoing quarter and 30.2% for the next. The company’s growth estimates for the current quarter and the next is a negative 108.3% and a negative 100%, respectively.

Fiverr’s Revenue

Year-on-year quarterly revenue growth grew by 89.2%, now sitting on 189.51M for the twelve trailing months.

Fiverr’s Stock Yearly Top and Bottom Value

Fiverr’s stock is valued at $34.55 at 17:32 EST, way under its 52-week low of $152.27.

Fiverr’s Moving Average

Fiverr’s value is way under its 50-day moving average of $181.37 and way below its 200-day moving average of $197.07.

More news about Fiverr.

6. Bionano Genomics (BNGO) – 13.47%

Bionano Genomics, Inc. is a company that develops and markets life science instruments in the genomic analysis industry. Saphyr, the company’s platform for ultrasensitive and specific structural variation detection, is developed and sold by the company. This allows clinicians and researchers to quickly search for diagnostic targets and new therapeutic targets. It also streamlines the analysis of changes in the chromosomes (also known as Cytogenetics). The Saphyr system comprises an instrument, consumables for chip chips, reagents and data analysis tools. Bionano pre- and labeling kit from the company provide critical protocols and reagents for extracting and labeling high-molecular-weight DNA to use with the Saphyr. The data solutions offer hardware and software that can be used for experiment management and algorithm development. The company sells products for research purposes primarily to labs associated with universities and government research institutions. The original name of the company was BioNano Genomics, Inc., but it changed its name in July 2018 to Bionano Genomics, Inc. Bionano Genomics, Inc. is an American company that was established in 2003. Its headquarters are in San Diego, California.

NASDAQ ended the session with Bionano Genomics jumping 13.47% to $1.39 on Thursday while NASDAQ jumped 0.06% to $11,370.96.

Volume

Today’s last reported volume for Bionano Genomics is 7724990 which is 5.7% above its average volume of 7307900.

Bionano Genomics’s last close was $1.23, 86.57% below its 52-week high of $9.12.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Bionano Genomics’s stock is considered to be overbought (>=80).

Bionano Genomics’s Stock Yearly Top and Bottom Value

Bionano Genomics’s stock is valued at $1.39 at 17:32 EST, below its 52-week low of $1.50.

Bionano Genomics’s Moving Average

Bionano Genomics’s worth is way below its 50-day moving average of $2.09 and way under its 200-day moving average of $3.88.

More news about Bionano Genomics.

7. Etsy (ETSY) – 12.98%

NASDAQ ended the session with Etsy jumping 12.98% to $87.91 on Thursday while NASDAQ rose 0.06% to $11,370.96.

Volume

Today’s last reported volume for Etsy is 9327440 which is 99.34% above its average volume of 4679110.

Etsy’s last close was $77.81, 74.72% below its 52-week high of $307.75.

Etsy’s Sales

Etsy’s sales growth is 11% for the current quarter and 20.3% for the next. The company’s growth estimates for the present quarter and the next is a negative 29.6% and a negative 15%, respectively.

Etsy’s Revenue

Year-on-year quarterly revenue growth grew by 16.2%, now sitting on 2.33B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Etsy’s stock is considered to be overbought (>=80).

Etsy’s Stock Yearly Top and Bottom Value

Etsy’s stock is valued at $87.91 at 17:32 EST, way below its 52-week high of $307.75 and above its 52-week low of $81.11.

Etsy’s Moving Average

Etsy’s value is way below its 50-day moving average of $125.18 and way under its 200-day moving average of $187.25.

More news about Etsy.

8. GENFIT S.A. (GNFT) – 12.7%

Genfit S.A. is a biopharmaceutical firm that develops therapeutic solutions and drug candidates for liver and metabolic diseases. Elafibranor is a product of the company. It’s currently in Phase 3 clinical trials to be used for primary biliary Cholangitis. NIS4 technology is also being developed by the company for diagnosing nonalcoholic steatohepatitis and fibrosis. Labcorp has signed a license agreement for NASHnext’s commercialization. This is a blood-based molecular diagnostic tool. Genfit S.A., which was founded in 1999, is located in Loos (France).

NASDAQ ended the session with GENFIT S.A. rising 12.7% to $3.55 on Thursday, following the last session’s upward trend. NASDAQ jumped 0.06% to $11,370.96, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Volume

Today’s last reported volume for GENFIT S.A. is 7480 which is 60.73% below its average volume of 19049.

GENFIT S.A.’s last close was $3.55, 44.36% under its 52-week high of $6.38.

GENFIT S.A.’s Revenue

Year-on-year quarterly revenue growth declined by 41.6%, now sitting on 5.32M for the twelve trailing months.

GENFIT S.A.’s Stock Yearly Top and Bottom Value

GENFIT S.A.’s stock is valued at $3.55 at 17:32 EST, way under its 52-week high of $6.38 and way above its 52-week low of $3.01.

GENFIT S.A.’s Moving Average

GENFIT S.A.’s value is below its 50-day moving average of $3.78 and under its 200-day moving average of $3.88.

More news about GENFIT S.A..

9. Novavax (NVAX) – 11.5%

Novavax, Inc., along with Novavax AB, a subsidiary, focuses on developing, commercializing and marketing vaccines that prevent serious infections. ResVax is a candidate for a vaccine against respiratory syncytial viruses (RSV), fusion (F), protein nanoparticles. It’s currently in Phase III clinical trials to prevent RSV infection in infants through maternal immunization. NanoFlu is also in Phase III clinical trials and can be used to treat seasonal influenza in elderly adults. Matrix-M is the company’s main adjuvant. It is used to increase the immune system attack against microorganisms and to immunize with lower levels of antigen. RSV F vaccine is being developed by the company for elderly (60+) and healthy children (6 months to 5 years old). Phase II clinical trials are ongoing. Phase I clinical trials are underway for both. It is also developing nanoparticle vaccine candidates to be used in clinic testing for the ebola virus. The company also has a COVID-19 vaccine being developed for the coronavirus, which causes symptoms similar to pneumonia. This is currently in preclinical phase. Novavax, Inc., was established in 1987. It is located in Gaithersburg, Maryland.

NASDAQ ended the session with Novavax rising 11.5% to $47.85 on Thursday while NASDAQ rose 0.06% to $11,370.96.

Volume

Today’s last reported volume for Novavax is 6330720 which is 39.37% above its average volume of 4542210.

Novavax’s last close was $42.92, 84.55% under its 52-week high of $277.80.

Novavax’s Sales

Novavax’s sales growth is 62.2% for the ongoing quarter and 232.9% for the next. The company’s growth estimates for the current quarter and the next is 85.2% and 250.2%, respectively.

Novavax’s Revenue

Year-on-year quarterly revenue growth declined by 20.5%, now sitting on 1.15B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Novavax’s stock is considered to be overbought (>=80).

Novavax’s Stock Yearly Top and Bottom Value

Novavax’s stock is valued at $47.85 at 17:32 EST, way under its 52-week high of $277.80 and way higher than its 52-week low of $42.13.

Novavax’s Moving Average

Novavax’s value is way below its 50-day moving average of $67.22 and way under its 200-day moving average of $145.41.

Previous days news about Novavax

  • Stocks making the biggest moves in the premarket: Peloton, Novavax, vroom and more. According to CNBC on Tuesday, 10 May, "The miss comes as Novavax shipped just 31 million Covid-19 vaccine doses during the quarter, putting it well off the pace of its projected 2 billion shots for 2022. "

More news about Novavax.

10. Groupon (GRPN) – 11.43%

Groupon, Inc. offers goods and services at discounted prices in North America as well as internationally through its online marketplaces. Groupon offers deals across a variety of categories including: events, activities, health, beauty and wellness, food and drink, home and garden, automotive, discounted rates and market rates on hotel and airfare as well as package and deal deals on electronics, sports goods, jewelry and toys. Customers can access its deals through websites, search engines, mobile apps and mobile. These allow consumers to view, buy, manage and redeem offers on mobile phones; email and push notifications, affiliate channels, social and display ads; offline marketing; and to make purchases. The original name of the company was ThePoint.com, Inc., but it changed its name in October 2008 to Groupon, Inc. Groupon, Inc. was established in 2008. It is located in Chicago, Illinois.

NASDAQ ended the session with Groupon rising 11.43% to $14.19 on Thursday while NASDAQ jumped 0.06% to $11,370.96.

Volume

Today’s last reported volume for Groupon is 2242550 which is 116.17% above its average volume of 1037380.

Groupon’s last close was $12.73, 74.46% below its 52-week high of $49.85.

Groupon’s Sales

Groupon’s sales growth is a negative 34.9% for the present quarter and a decline by 7.6% for the next. The company’s growth estimates for the current quarter is a negative 62.7% and positive 112% for the next.

Groupon’s Revenue

Year-on-year quarterly revenue growth declined by 29.6%, now sitting on 1.09B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Groupon’s stock is considered to be overbought (>=80).

Groupon’s Stock Yearly Top and Bottom Value

Groupon’s stock is valued at $14.19 at 17:32 EST, way under its 52-week low of $16.37.

Groupon’s Moving Average

Groupon’s worth is way under its 50-day moving average of $19.31 and way under its 200-day moving average of $23.25.

More news about Groupon.

Most Active Losers Today

1. FAT Brands (FATBW) – -31.11%

NASDAQ ended the session with FAT Brands sliding 31.11% to $3.41 on Thursday while NASDAQ rose 0.06% to $11,370.96.

FAT Brands’s last close was $3.41, 0% below its 52-week high of $3.41.

FAT Brands’s Stock Yearly Top and Bottom Value

FAT Brands’s stock is valued at $3.41 at 17:32 EST, under its 52-week low of $3.41.

More news about FAT Brands.

2. Helius Medical Technologies (HSDT) – -23.71%

Helius Medical Technologies, Inc. is a company that develops, licenses, and acquires non-invasive technology for treating neurological diseases or trauma symptoms. The company’s product, the Portable Neuromodulation Stimulator (PoNS), a medical device that is not implantable, was designed to treat gait problems caused by multiple sclerosis or balance issues due to mild-to moderate traumatic brain injuries. It can also be used with therapeutic exercise. Newtown is the headquarters of this company.

NASDAQ ended the session with Helius Medical Technologies dropping 23.71% to $1.48 on Thursday while NASDAQ jumped 0.06% to $11,370.96.

Volume

Today’s last reported volume for Helius Medical Technologies is 38078 which is 96.36% above its average volume of 19391.

Helius Medical Technologies’s last close was $1.94, 88.76% below its 52-week high of $17.26.

Helius Medical Technologies’s Revenue

Year-on-year quarterly revenue growth grew by 35.1%, now sitting on 522k for the twelve trailing months.

Helius Medical Technologies’s Stock Yearly Top and Bottom Value

Helius Medical Technologies’s stock is valued at $1.48 at 17:33 EST, way below its 52-week high of $17.26 and higher than its 52-week low of $1.45.

Helius Medical Technologies’s Moving Average

Helius Medical Technologies’s worth is way below its 50-day moving average of $3.11 and way under its 200-day moving average of $8.11.

More news about Helius Medical Technologies.

3. Greenrose Acquisition Corp. (GNRS) – -16%

Greenrose Acquisition Corp. doesn’t have any significant operations. The company plans to merge, exchange shares, acquire assets, stock buy, recapitalization and reorganize with other businesses. It was founded in Amityville in New York in 2019.

NASDAQ ended the session with Greenrose Acquisition Corp. falling 16% to $1.05 on Thursday while NASDAQ rose 0.06% to $11,370.96.

Volume

Today’s last reported volume for Greenrose Acquisition Corp. is 300 which is 93.06% below its average volume of 4326.

Greenrose Acquisition Corp.’s last close was $1.25, 88.23% under its 52-week high of $10.62.

Greenrose Acquisition Corp.’s Stock Yearly Top and Bottom Value

Greenrose Acquisition Corp.’s stock is valued at $1.05 at 17:33 EST, below its 52-week low of $1.05.

Greenrose Acquisition Corp.’s Moving Average

Greenrose Acquisition Corp.’s value is way below its 50-day moving average of $3.44 and way under its 200-day moving average of $6.47.

More news about Greenrose Acquisition Corp..

4. Esports Entertainment Group (GMBLW) – -15.48%

NASDAQ ended the session with Esports Entertainment Group falling 15.48% to $0.16 on Thursday while NASDAQ rose 0.06% to $11,370.96.

Esports Entertainment Group’s last close was $0.16, 6.89% under its 52-week high of $0.17.

Esports Entertainment Group’s Stock Yearly Top and Bottom Value

Esports Entertainment Group’s stock is valued at $0.16 at 17:33 EST, under its 52-week high of $0.17 and way higher than its 52-week low of $0.11.

More news about Esports Entertainment Group.

5. TherapeuticsMD (TXMD) – -13.63%

TherapeuticsMD, Inc. is a United States women’s health company. The company provides IMVEXXY, a treatment for moderate-to severe dyspareunia, and BIJUVA which is a bioidentical hormonal therapy combination of 17AY-estradiol, progesterone, for moderate to severe vasomotor symptoms. TX-015HR is a transdermal patch candidate that contains progesterone and estradiol. TX-009HR is the company’s clinical product. It contains an oral progesterone/estradiol formula. The company also produces and distributes generic and branded prescription prenatal vitamins under the vitaTrue and vitaMedMD brands. It sells prescription hormone therapy drugs and prenatal vitamins to both wholesale and retail pharmacie distributors. TherapeuticsMD, Inc., is located in Boca Raton, Florida.

NASDAQ ended the session with TherapeuticsMD sliding 13.63% to $2.99 on Thursday while NASDAQ jumped 0.06% to $11,370.96.

Volume

Today’s last reported volume for TherapeuticsMD is 1164430 which is 442.97% above its average volume of 214455.

TherapeuticsMD’s last close was $3.46, 25.82% higher than its 52-week high of $2.75.

TherapeuticsMD’s Sales

TherapeuticsMD’s sales growth is 33.7% for the present quarter and 29.3% for the next. The company’s growth estimates for the current quarter and the next is 16.7% and 40%, respectively.

TherapeuticsMD’s Revenue

Year-on-year quarterly revenue growth grew by 114.9%, now sitting on 84.79M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

TherapeuticsMD’s stock is considered to be oversold (<=20).

TherapeuticsMD’s Stock Yearly Top and Bottom Value

TherapeuticsMD’s stock is valued at $2.99 at 17:33 EST, higher than its 52-week high of $2.75.

TherapeuticsMD’s Moving Average

TherapeuticsMD’s worth is way higher than its 50-day moving average of $0.66 and way above its 200-day moving average of $1.00.

More news about TherapeuticsMD.

6. Fortress Biotech (FBIO) – -13.25%

Fortress Biotech, Inc. is a biopharmaceutical firm that develops and markets pharmaceutical and biotechnology products. Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes dermatology products. These include Ximino capsules which treat only inflammatory lesion of moderate-to severe acne vulgaris. Targadox cream treats severe ringworm symptoms. Exelderm cream treats jock itch; Ceracade treats dry skin conditions. Luxamend can be used to manage wounds and dressings. Accutane capsules are for severe recalcitrant or nodular cysts. The company also produces late-stage product candidates such as intravenous Tramadol to treat post-operative pain, CUTX101 and MB207 to treat X-linked severe combined immune deficiency, and Cosibelimab, which are used for patients suffering from EGFR mutations-positive NSCLC. MB102 is a blastic plasmacytoid cell neoplasm, MB101 for glioblastoma, MB104 for multiple myeloma, and light chain Amyloidosis. MB103 can be used to treat GBM & metastatic cancer to the brain. MB108 and MB105 are for pancreatic and prostate cancers. BAER-101 is for severe traumatic brain injury in children and adults. Preclinical products include AAV-ATP7A gene treatment; AVTS-011 gene therapy; CK103 BET inhibitor, CEVAD and CEVA-102, CK-302, anti-GITR, CK303, ConVax, ONCOlogues and CK-101. There are collaboration agreements with universities and research institutes as well as pharmaceutical companies. The former name of the company was Coronado Biosciences, Inc., but it changed its name in April 2015 to Fortress Biotech, Inc. Fortress Biotech, Inc., was founded in 2006. It is located in New York, New York.

NASDAQ ended the session with Fortress Biotech dropping 13.25% to $0.80 on Thursday while NASDAQ rose 0.06% to $11,370.96.

Volume

Today’s last reported volume for Fortress Biotech is 759494 which is 21.83% above its average volume of 623395.

Fortress Biotech’s last close was $0.80, 82.11% below its 52-week high of $4.49.

Fortress Biotech’s Sales

Fortress Biotech’s sales growth is 251.4% for the current quarter and a decline by 16.2% for the next. The company’s growth estimates for the present quarter and the next is 460% and 9.1%, respectively.

Fortress Biotech’s Revenue

Year-on-year quarterly revenue growth grew by 122.5%, now sitting on 64.26M for the twelve trailing months.

Fortress Biotech’s Stock Yearly Top and Bottom Value

Fortress Biotech’s stock is valued at $0.80 at 17:33 EST, below its 52-week low of $0.80.

Fortress Biotech’s Moving Average

Fortress Biotech’s worth is way under its 50-day moving average of $1.25 and way below its 200-day moving average of $2.43.

More news about Fortress Biotech.

7. Second Sight Medical Products (EYESW) – -12.12%

NASDAQ ended the session with Second Sight Medical Products sliding 12.12% to $0.44 on Thursday, after five successive sessions in a row of losses. NASDAQ rose 0.06% to $11,370.96, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.

Second Sight Medical Products’s last close was $0.44, 10.33% below its 52-week high of $0.49.

Second Sight Medical Products’s Stock Yearly Top and Bottom Value

Second Sight Medical Products’s stock is valued at $0.44 at 17:33 EST, way below its 52-week high of $0.49 and way above its 52-week low of $0.24.

More news about Second Sight Medical Products.

8. Foresight Autonomous Holdings Ltd. (FRSX) – -11.14%

Foresight Autonomous Holdings Ltd. is a technology company that designs, develops, and markets sensor systems to the Israeli and Chinese automotive industries. The company develops cellular-based applications and vision systems that are within-line of sight. The company offers QuadSight system, a quad-camera multi-spectral vision system for the semi-autonomous and autonomous vehicle market; V2X (vehicle-to-everything), an accident prevention solution based on real-time multi-agents positioning algorithms that enables communication between vehicles, infrastructure, grid, home, and network; and Eye-Net Protect, a cellular-based V2X solution that provides real-time pre-collision alerts to vulnerable road users, such as pedestrians, cyclists, scooter drivers, etc. By using smartphones. To develop, market, distribute, and support QuadSight, the company has entered into a strategic cooperation arrangement with FLIR Systems, Inc. The former name of the company was Asia Development (A.D.B.M.). Ltd., and changed its name in 2016 to Foresight Automotive Holdings Ltd. Foresight Autonomous Holdings Ltd., which was established in 1977, is located in Ness Ziona in Israel.

NASDAQ ended the session with Foresight Autonomous Holdings Ltd. dropping 11.14% to $0.59 on Thursday while NASDAQ rose 0.06% to $11,370.96.

Volume

Today’s last reported volume for Foresight Autonomous Holdings Ltd. is 727638 which is 62.36% above its average volume of 448149.

Foresight Autonomous Holdings Ltd.’s last close was $0.59, 89.63% below its 52-week high of $5.69.

The company’s growth estimates for the ongoing quarter is a negative 200% and positive 14.3% for the next.

Foresight Autonomous Holdings Ltd.’s Stock Yearly Top and Bottom Value

Foresight Autonomous Holdings Ltd.’s stock is valued at $0.59 at 17:33 EST, below its 52-week low of $0.59.

Foresight Autonomous Holdings Ltd.’s Moving Average

Foresight Autonomous Holdings Ltd.’s value is way below its 50-day moving average of $0.98 and way under its 200-day moving average of $2.08.

More news about Foresight Autonomous Holdings Ltd..

9. Esports Entertainment Group (GMBL) – -10.93%

Esports Entertainment Group, Inc. is an Canadian online gambling business. It offers esports entertainment and esports betting, as well traditional and professional esports events. Vie.gg is an online betting site for esports. The company used to be known as VGambling, Inc. but changed its name in May 2017 to Esports Entertainment Group, Inc. Esports Entertainment Group, Inc., was founded in 2008. It is located in Birkirkara, Malta.

NASDAQ ended the session with Esports Entertainment Group dropping 10.93% to $0.38 on Thursday while NASDAQ rose 0.06% to $11,370.96.

Volume

Today’s last reported volume for Esports Entertainment Group is 965316 which is 38.82% below its average volume of 1577950.

Esports Entertainment Group’s last close was $0.38, 97.22% below its 52-week high of $13.74.

The company’s growth estimates for the present quarter and the next is 47.4% and 67.1%, respectively.

Esports Entertainment Group’s Revenue

Year-on-year quarterly revenue growth grew by 515.2%, now sitting on 45.14M for the twelve trailing months.

Esports Entertainment Group’s Stock Yearly Top and Bottom Value

Esports Entertainment Group’s stock is valued at $0.38 at 17:33 EST, way under its 52-week high of $13.74 and above its 52-week low of $0.37.

Esports Entertainment Group’s Moving Average

Esports Entertainment Group’s value is way below its 50-day moving average of $0.68 and way under its 200-day moving average of $4.43.

More news about Esports Entertainment Group.

10. Forte Biosciences (FBRX) – -10.89%

Forte Biosciences Inc. is a US-based clinical-stage biopharmaceutical firm. The company is currently developing a biotherapeutic FB-401, which has successfully completed the Phase 1/2a clinical study to treat inflammatory skin conditions in children with atopic dermatitis. Torrance is the home of this company, which was founded in 2007.

NASDAQ ended the session with Forte Biosciences falling 10.89% to $1.10 on Thursday while NASDAQ jumped 0.06% to $11,370.96.

Volume

Today’s last reported volume for Forte Biosciences is 198170 which is 26.48% above its average volume of 156673.

Forte Biosciences ‘s last close was $1.11, 97.46% below its 52-week high of $43.57.

The company’s growth estimates for the present quarter and the next is 8.1% and 44.4%, respectively.

Forte Biosciences ‘s Stock Yearly Top and Bottom Value

Forte Biosciences ‘s stock is valued at $1.10 at 17:33 EST, below its 52-week low of $1.10.

Forte Biosciences ‘s Moving Average

Forte Biosciences ‘s value is way below its 50-day moving average of $1.37 and way below its 200-day moving average of $5.78.

More news about Forte Biosciences .

Stay up to date with our winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here